Search results for "22"

showing 10 items of 13984 documents

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After All…

2020

Currently, the prognosis of Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients relapsing after an allogenic hematopoietic stem cell transplantation (allo-SCT) remains poor, with few therapeutic options available. Here we present the case of a 32 years old patient with dasatinib-resistant post-transplant molecular relapse of ALL, who received, as second-line therapy, the combination of ponatinib and donor lymphocyte infusion (DLI). The therapy was safe and the patient achieved a sustained minimal residual disease negative disease, still ongoing after 22 months, which was accompanied by several changes in the immune populations distribution within the bone marrow (i.e., the increase in the C…

0301 basic medicineOncologymedicine.medical_specialtyCancer Researchmedicine.medical_treatmentT lymphocytesCase ReportHematopoietic stem cell transplantationlcsh:RC254-282Donor lymphocyte infusionbone marrow microenviroment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineacute lymhoblastic leukemiaInternal medicinehemic and lymphatic diseasesT lymphocytemedicineponatinibbusiness.industryPonatinibDonor Lymphocyteslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDasatinib030104 developmental biologymedicine.anatomical_structurechemistryOncology030220 oncology & carcinogenesisdonor lymphocyte infusion (DLI)Bone marrowStem cellbusinessCD8medicine.drugFrontiers in Oncology
researchProduct

Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families

2021

(1) Background: Over the last decade, genetic counseling clinics have moved from single-gene sequencing to multigene panel sequencing. Multiple genes related to a moderate risk of breast cancer (BC) have emerged, although many questions remain regarding the risks and clinical features associated with these genes. (2) Methods: Ninety-six BC index cases (ICs) with high-risk features for hereditary breast and ovarian cancer (HBOC) and with a previous uninformative result for BRCA1/2 were tested with a panel of 41 genes associated with BC risk. The frequency of pathogenic variants (PVs) was related to the clinical characteristics of BC. (3) Results: We detected a PV rate of 13.5% (excluding two…

0301 basic medicineOncologymedicine.medical_specialtyCandidate geneGenetic counselingMedicine (miscellaneous)germline testingmoderate penetrance geneshereditary breast and ovarian cancerArticle03 medical and health sciences0302 clinical medicineBreast cancerMUTYHInternal medicinemedicineCHEK2BRCA1 or BRCA2 negativebusiness.industryRBRIP1medicine.disease030104 developmental biologyMSH2030220 oncology & carcinogenesisCohortMedicinenext-generation sequencingbusinessJournal of Personalized Medicine
researchProduct

Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.

2018

Abstract Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate stage HCC, including those with large or multinodular HCC, well-preserved liver function, and no cancer-related symptoms or evidence of vascular invasion or extrahepatic spread. Two TACE techniques have been used since 2004, convent…

0301 basic medicineOncologymedicine.medical_specialtyCarcinoma Hepatocellular03 medical and health sciences0302 clinical medicineInternal medicineCarcinomamedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)Chemoembolization TherapeuticPerformance statusbusiness.industryLiver NeoplasmsCancerGeneral Medicinemedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomaLipiodolLiver functionLiver cancerbusinessmedicine.drugCancer treatment reviews
researchProduct

Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology.

2021

The HIPPO pathway (HP) is a highly conserved kinase cascade that affects organ size by regulating proliferation, cell survival and differentiation. Discovered in Drosophila melanogaster to early 2000, it immediately opened wide frontiers in the field of research. Over the last years the field of knowledge on HP is quickly expanding and it is thought will offer many answers on complex pathologies. Here, we summarized the results of several studies that have investigated HP signaling both in oncology than in cardiology field, with an overview on future perspectives in cardiology research.

0301 basic medicineOncologymedicine.medical_specialtyCardiologyProtein Serine-Threonine KinasesCardiac regeneration03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsHumansHippo Signaling PathwayCardio oncologyCell survivalCell ProliferationHippo signaling pathwaybiologybusiness.industryHematologybiology.organism_classificationKinase cascade030104 developmental biologyDrosophila melanogasterOncologyCardiology fieldAnimals Cardiac development Cardiac regeneration Cardio-oncology Cardiology Cell Proliferation Drosophila melanogaster HIPPO signaling pathway Humans Protein Serine-Threonine Kinases030220 oncology & carcinogenesisCardiologyDrosophila melanogasterbusinessSignal TransductionCritical reviews in oncology/hematology
researchProduct

The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.

2018

The term liquid biopsy refers to the analysis of biomarkers in any body fluid, including blood, urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor-derived DNA, RNA, miRNA and proteins that can be either cell-free or contained in circulating tumor cells (CTC), extracellular vesicles (EVs) or platelets. A number of studies suggest that liquid biopsy testing could have a relevant role in the management of colorectal cancer (CRC) patients at different stages of the disease. Analysis of cell-free DNA (cfDNA), CTC and/or miRNA can provide relevant information for the early diagnosis of CRC and the identification of minimal residual disease and, more gener…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerDiseaseColorectal NeoplasmPredictivePrognosticSomatic evolution in cancer03 medical and health sciences0302 clinical medicineCirculating tumor cellInternal medicinemedicineCell-Free Nucleic AcidBiomarkers TumorHumansRadiology Nuclear Medicine and imagingLiquid biopsybusiness.industryLiquid BiopsyCancerDisease ManagementGeneral MedicineBiomarkerDNA Neoplasmmedicine.diseaseMinimal residual disease3. Good healthColorectal carcinoma030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)businessColorectal NeoplasmsCell-Free Nucleic AcidsHumanCancer treatment reviews
researchProduct

Prognostic impact and implications of extra-capsular lymph node involvement in colorectal cancer: a systematic review with meta-analysis.

2015

The extranodal extension (ENE) of nodal metastasis (i.e. the extension of tumor cells through the nodal capsule into the perinodal adipose tissue) has recently emerged as an important prognostic factor in different types of malignancies. However, the tumor-node-metastasis (TNM) staging system for colorectal cancer does not consider it as a prognostic parameter. Therefore, we conducted a systematic review and meta-analysis to determine the prognostic role of ENE in patients with lymph node-positive colorectal cancer.Two independent authors searched PubMed and SCOPUS until 7 January 2015 without language restrictions. Prospective studies reporting data on prognostic parameters in subjects wit…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerExtra-capsular extensionColon cancer; ENE; Extra-capsular extension; Extra-nodal extension; Lymph node metastasis; Rectal cancer03 medical and health sciences0302 clinical medicinecolon cancer; extracapsular extension; extranodal extension; lymph node metastasis; rectal cancerInternal medicineHumansMedicineextracapsular extensionRectal cancerProspective cohort studyLymph nodeProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelHazard ratioCancerextranodal extensionHematologyPrognosismedicine.diseaseColon cancerTreatment Outcome030104 developmental biologymedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisMeta-analysisENEextranodal extension extracapsular extension lymph node metastasis colon cancer rectal cancerRegression AnalysisT-stageExtra-nodal extensionLymph NodesNeoplasm Recurrence LocalColorectal Neoplasmsbusiness
researchProduct

Innovative Therapeutic Strategies Targeting Colorectal Cancer Stem Cells

2017

Colorectal cancer is the fourth most common cause of cancer-related death. Although many advances in the treatment of this disease have been made, a large number of patients develop metastasis and resistance to current therapies. The current evidence indicates that cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT) have crucial roles in colorectal carcinogenesis and metastasis. It is also very important to understand the mechanisms that allow the survival of CSCs, such as metabolic reprogramming, which permits them to obtain specific properties or the activation of alternative signaling pathways in response to first-line therapies. In this review, we discuss the failure…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerMetabolic reprogrammingDiseaseMultidrug resistanceTarget therapyMetastasis03 medical and health sciences0302 clinical medicineCancer stem cellInternal medicineMedicineOxidative phosphorylationHepatologybusiness.industryCancer stem cellEMTGastroenterologyColorectal carcinogenesismedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellStem cellbusinessCurrent Colorectal Cancer Reports
researchProduct

Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) p…

2018

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerbusiness.industryHematologymedicine.diseaseIrinotecan03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyFluorouracil030220 oncology & carcinogenesisInternal medicinemedicineFOLFIRIFirst line chemotherapybusinessAfliberceptmedicine.drugAnnals of Oncology
researchProduct

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision

2017

Curative treatment of rectal cancer depends on an optimal surgical resection, with the addition of neoadjuvant radiotherapy (RT) with or without concomitant chemotherapy (ChT) in more advanced tumors. The role of adjuvant ChT is controversial and a more intensified neoadjuvant approach with the addition of ChT before or after RT, or even as single modality, is currently being explored in trials. A systematic review selecting randomised phase II and III trials on the role of ChT in localized rectal cancer was performed. Data show that neoadjuvant ChRT improves locoregional control in resected rectal cancer. Short-course RT (SCRT) could give similar outcomes to ChRT. The addition of oxaliplat…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAntineoplastic Agents03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicPreoperative chemoradiationInternal medicineMedicineCombined Modality TherapyHumansRadiology Nuclear Medicine and imagingRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicChemotherapybusiness.industryRectal NeoplasmsGeneral MedicineAdjuvant chemotherapy; Preoperative chemoradiation; Rectal cancermedicine.diseaseCombined Modality TherapyNeoadjuvant TherapyOxaliplatinAdjuvant chemotherapyRadiation therapy030104 developmental biologyOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisConcomitantRadiotherapy AdjuvantbusinessAdjuvantmedicine.drug
researchProduct

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis

2018

Background: At present, there is uncertainty on the best systemic treatment in first-line setting for RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients. Indeed, several chemotherapy and biologics combinations showed an improvement on survival. We performed a systematic review with a pair-wise and bayesan meta-analysis to rank the best strategy for these patients. Methods: A systematic literature search through March 2017 was performed to evaluate the association between several treatment combinations and overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity rate (TR) in RAS WT mCRC patients. Data were extracted from studies and pooled…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentBayesian probabilitySidednessDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientMeta-analysiSystemic chemotherapyNeoplasm MetastasisRAS wild-typeChemotherapyVbusiness.industryMetastatic colorectal cancerWild typeBayes TheoremHematologymedicine.diseaseNeoadjuvant TherapyFirst line treatmentMeta-analysisSafety profileGenes ras030104 developmental biologyOncology030220 oncology & carcinogenesisMeta-analysisSystemic chemotherapy.Colorectal Neoplasmsbusiness
researchProduct